Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy?

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Yeka, A.
dc.contributor.author Achan, J.
dc.contributor.author D'Alessandro, U.
dc.contributor.author Talisuna, A. O.
dc.date.accessioned 2009-08-26T08:07:24Z
dc.date.available 2009-08-26T08:07:24Z
dc.date.issued 2009
dc.identifier.issn 1473-3099
dc.identifier.doi http://dx.doi.org/10.1016/S1473-3099(09)70109-4
dc.identifier.other ITG-P3A
dc.identifier.other ITG-PLB
dc.identifier.other PARAS
dc.identifier.other U-MALAR
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other UPD16
dc.identifier.other ABSTRACT
dc.identifier.uri http://hdl.handle.net/10390/2761
dc.description.abstract Several African countries that have adopted artemisinin-based combination therapy (ACT) as first-line treatment of uncomplicated Plasmodium falciparum malaria also use quinine monotherapy as second-line therapy. This policy goes against WHO recommendations for combination therapy and could be considered an inappropriate public health policy. Adherence to a 7-day quinine treatment schedule is likely to be poor and may increase the risk of selecting resistant parasites. Furthermore, because quinine has limited post-treatment prophylaxis, it will not prevent, in areas of intense transmission, recurrent malaria infections, which can lead to additional morbidity, including anaemia. Therefore, ACTs and not quinine should be used as second-line treatment, because these are well tolerated, highly efficacious, and have the advantage of reducing gametocyte carriage and consequently malaria transmissibility, particularly in areas of less intense transmission. en
dc.language English en
dc.subject Protozoal diseases en
dc.subject Malaria en
dc.subject Plasmodium falciparum en
dc.subject Drug therapy en
dc.subject National policies en
dc.subject First-line drugs en
dc.subject Artemisinin combination therapies (ACT) en
dc.subject Second-line drugs en
dc.subject Quinine en
dc.subject Monotherapy en
dc.subject WHO strategy en
dc.subject Compliance en
dc.subject Drug resistance en
dc.subject Efficacy en
dc.subject Transmissibility en
dc.subject Recurrence en
dc.subject Tolerability en
dc.subject Africa, General en
dc.title Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? en
dc.type Article en
dc.citation.issue 7 en
dc.citation.jtitle Lancet Infectious Diseases en
dc.citation.volume 9 en
dc.citation.pages 448-452 en
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/19555904
dc.citation.jabbreviation Lancet Infect Dis en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record